Dr. Kirk Schultz is a Professor at the University of British Columbia, BC Children’s Hospital Research Institute, and an elected fellow of the Canadian Academy of Health Sciences. Dr. Schultz is a Pediatric Hematologist/Oncologist focused on new therapies and rejection in Blood and Marrow Transplantation (BMT) and immune therapy of blood cancers. Dr. Schultz is a past recipient of the CIHR/Wyeth Clinical Research Chair in Transplantation, past chair of the Pediatric BMT Consortium the largest children’s BMT clinical trials group world-wide, and president-elect of Cell Therapy and Transplantation Canada (CTTC), the national group for Canadian cell therapy and BMT. Dr. Schultz was the co-chair of the 2020 NIH cGvHD Consensus meeting and past chair of the Biomarkers working group for the previous 2 Consensus meetings (2004 & 2014). Dr. Schultz was the Team leader for the pediatric Applied Biomarkers in Late Effects (ABLE) Team grant (2011 – 2016; $4.3M Canadian Institutes of Health Research (CIHR) funded). Dr. Schultz has 219 publications and 2 CIHR Grants and other smaller funding.